The provision will see Teijin Pharma, a medical and pharmaceuticals business subsidiary of Teijin, update their existing system for archiving small molecules by implementing the JChem platform. The JChem platform will better enable Teijin to develop more powerful solutions for Teijin's research activities worldwide. The adoption of the JChem platform for small molecule storage and search constitutes a step forward in this process.

"We are pleased with the performance and potential of the JChem tools in our system, the functions are particularly suitable for distributed, enterprise class solutions." commented Dr. Hiroshi Kawabata, Ph.D., Senior Manager, Medicinal Chemistry Research Department, Pharmaceutical Discovery Research Laboratories at Teijin Pharma Limited.

"We are very happy that our science and functionality is relevant to Teijin, particularly given its scale and scope. Commercially we believe that this switch may fully open the door for further adoptions in Japan and would mirror our experience with clients globally" commented Dr Ferenc Csizmadia, CEO of ChemAxon.

About ChemAxon
ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information visit http://www.chemaxon.com/

About Teijin Group and its Pharmaceutical subsidiary
The Teijin Group is active in a wide range of businesses, including fibers, films, plastics, pharmaceuticals and home health care and information technology (IT)-related services.
Teijin Pharma, medical and pharmaceuticals business subsidiary of Teijin, focuses on the three key therapeutic areas: respiratory, bone/joint, and cardiovascular/metabolic diseases. In the respiratory field, Teijin Pharma has strong R&D and marketing position with pharmaceutical products and home oxygen therapy (HOT) business, which has a top market share in Japan. Teijin Pharma is now trying to expand its product pipeline for COPD/asthma by in-licensing as well as in-house R&D; it will continue to pursue providing total health care services for these patients through synergistic activities in the pharmaceuticals and HOT businesses.